Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M B Atkins

Showing results (11-20 of 101) with videos related to

Pageof 11
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 7, 2017
Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directionsM B Atkins, J I Clark, D I Quinn
Cancer Chemotherapy and Biological Response Modifiers|November 1, 2001
Clinical use of systemic IL-12 therapyJ A Gollob, J W Mier, M B Atkins
Radiology|November 30, 1999
Liver metastases from melanoma: detection with multiphasic contrast-enhanced CTS P Blake, K Weisinger, M B Atkins, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|August 1, 1995
Severe reversible global and regional ventricular dysfunction associated with high-dose interleukin-2 immunotherapyJ S Du Bois, J E Udelson, M B Atkins
The Cancer Journal From Scientific American|February 24, 2000
High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival updateM B Atkins, L Kunkel, M Sznol, et al.
The New England Journal of Medicine|April 5, 1990
An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapyM S Klempner, R Noring, J W Mier, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 1, 1992
Leukotriene C4 uses a probenecid-sensitive export carrier that does not recognize leukotriene B4B K Lam, K Xu, M B Atkins, et al.
The American Journal of Medicine|June 1, 1992
Chronic inflammatory arthritis after treatment with high-dose interleukin-2 for malignancyE M Massarotti, N Y Liu, J Mier, et al.
Cytokine|October 1, 1995
Induction of circulating interleukin 10 by interleukin 1 and interleukin 2, but not interleukin 6 immunotherapyH Tilg, M B Atkins, C A Dinarello, et al.
Transfusion|July 1, 1989
Lymphokine-activated killer cell generation and recovery. Comparison of an automated cell processing device and a manual procedureT Ryan, M B Atkins, J W Mier, et al.
Pageof 11

Showing results (11-20 of 101) with videos related to

Sort By:
Pageof 11
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 7, 2017
Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directionsM B Atkins, J I Clark, D I Quinn
Cancer Chemotherapy and Biological Response Modifiers|November 1, 2001
Clinical use of systemic IL-12 therapyJ A Gollob, J W Mier, M B Atkins
Radiology|November 30, 1999
Liver metastases from melanoma: detection with multiphasic contrast-enhanced CTS P Blake, K Weisinger, M B Atkins, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|August 1, 1995
Severe reversible global and regional ventricular dysfunction associated with high-dose interleukin-2 immunotherapyJ S Du Bois, J E Udelson, M B Atkins
The Cancer Journal From Scientific American|February 24, 2000
High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival updateM B Atkins, L Kunkel, M Sznol, et al.
The New England Journal of Medicine|April 5, 1990
An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapyM S Klempner, R Noring, J W Mier, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 1, 1992
Leukotriene C4 uses a probenecid-sensitive export carrier that does not recognize leukotriene B4B K Lam, K Xu, M B Atkins, et al.
The American Journal of Medicine|June 1, 1992
Chronic inflammatory arthritis after treatment with high-dose interleukin-2 for malignancyE M Massarotti, N Y Liu, J Mier, et al.
Cytokine|October 1, 1995
Induction of circulating interleukin 10 by interleukin 1 and interleukin 2, but not interleukin 6 immunotherapyH Tilg, M B Atkins, C A Dinarello, et al.
Transfusion|July 1, 1989
Lymphokine-activated killer cell generation and recovery. Comparison of an automated cell processing device and a manual procedureT Ryan, M B Atkins, J W Mier, et al.
Pageof 11